BTG Specialty Pharmaceuticals is again trying to secure EU marketing approval for Voraxaze (glucarpidase), its treatment for cancer patients at risk of methotrexate toxicity. The company’s first attempt was around 15 years ago. The product was approved in the US in 2012.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?